Laboratory of Tumor Immunology, Department of Oncology, University Hospital Zurich, Zurich, Switzerland.
Clin Cancer Res. 2010 Jul 15;16(14):3562-70. doi: 10.1158/1078-0432.CCR-09-3136. Epub 2010 Jun 2.
Nonmelanoma skin cancer is the most common cancer and comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The incidence of SCC increases drastically in immunosuppressed individuals, suggesting a critical role of the immune system in controlling SCC. To find an explanation for the selective immunosurveillance of SCC, we investigated the expression of cancer-testis (CT) antigens and MHC class I (MHC-I) and the infiltration by immune cells in BCC and SCC.
We determined the expression of 23 different CT-antigens in 63 BCC and 40 SCC biopsies of immunocompetent and in 20 biopsies of immunosuppressed SCC patients by reverse transcription-PCR and immunohistochemistry. IgG responses to 36 tumor antigens were measured by Western blotting and ELISA. MHC-I expression and CD8(+) T-cell infiltration were analyzed by immunohistochemistry in BCC and SCC of immunocompetent and immunosuppressed patients and in imiquimod-treated BCC patients.
We found expression of at least one CT-antigen in 81% of BCC and in 40% of SCC. We did not detect CT-antigen-specific serum IgG. Most SCC, but not BCC, expressed MHC-I and were infiltrated with CD8(+) cells. Imiquimod-treated BCC expressed MHC-I and were infiltrated by CD8(+) T cells.
We propose that immunosurveillance controls SCC, but not BCC, because the latter lacks MHC-I. This fits with the increased incidence of SCC in immunosuppressed individuals and may explain the relatively low prevalence of CT-antigen expression in SCC as a result of CD8(+) T-cell-driven immunoediting.
非黑色素瘤皮肤癌是最常见的癌症,包括基底细胞癌 (BCC) 和鳞状细胞癌 (SCC)。在免疫抑制个体中,SCC 的发病率急剧增加,这表明免疫系统在控制 SCC 方面起着关键作用。为了找到 SCC 选择性免疫监视的解释,我们研究了癌症睾丸抗原 (CT) 和 MHC Ⅰ类 (MHC-Ⅰ) 的表达以及 BCC 和 SCC 中免疫细胞的浸润。
我们通过逆转录-PCR 和免疫组织化学检测了 63 例 BCC 和 40 例 SCC 免疫功能正常和 20 例免疫抑制 SCC 患者活检中 23 种不同 CT 抗原的表达。通过 Western blot 和 ELISA 测定了针对 36 种肿瘤抗原的 IgG 反应。在免疫功能正常和免疫抑制患者的 BCC 和 SCC 以及咪喹莫特治疗的 BCC 中,通过免疫组织化学分析了 MHC-Ⅰ表达和 CD8+T 细胞浸润。
我们发现至少有一种 CT 抗原在 81%的 BCC 和 40%的 SCC 中表达。我们未检测到 CT 抗原特异性血清 IgG。大多数 SCC,但不是 BCC,表达 MHC-Ⅰ并被 CD8+细胞浸润。咪喹莫特治疗的 BCC 表达 MHC-Ⅰ并被 CD8+T 细胞浸润。
我们提出免疫监视控制 SCC,但不控制 BCC,因为后者缺乏 MHC-Ⅰ。这与免疫抑制个体中 SCC 发病率增加相符,并且可能解释了 SCC 中 CT 抗原表达相对较低的原因,这是由于 CD8+T 细胞驱动的免疫编辑所致。